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Summary 
CD4 + and CD8 § or/j3 §  T  cells of the T  helper cell (Th)2 phenotype produce the cytokines 
IL-4, IL-5, and IL-13 that promote IgE production and eosinophilic inflammation. IL-4 may 
play an important role in mediating the differentiation of antigenically naive or/J3  + T  cells into 
Th2 cells. Murine NKI.1 + (CD4 + or CD4-CD8-) e~/[3  + T  ceils comprise a J32-microglobulin 
([32m)-dependent cell population that rapidly produces IL-4 after cell activation in vitro and in 
vivo and has been proposed as a source oflL-4 for Th2 cell differentiation. 0t/J3  + CD8 § T  cells, 
most of which require [32m for their development, have also been proposed as positive regula- 
tors of allergen-induced Th2 responses. We tested whether [32m-dependent T  cells were essen- 
tial for Th2 cell-mediated allergic reactions by treating wild-type, [32m-deficient (~2m -/-),  and 
IL-4-deficient (IL-4 -/-)  mice of the C57BL/6 genetic background with ovalbumin (OVA), 
using  a  protocol that  induces  robust  allergic  pulmonary  disease  in  wild-type  mice.  OVA- 
treated ~2m  -/-  mice had circulating levels of total and OVA-specific IgE, pulmonary eosi- 
nophilia, and expression of IL-4, IL-5, and IL-13 mtkNA in bronchial lymph node tissue sim- 
ilar  to  that  of OVA-treated  wild-type  mice.  In  contrast,  these  responses in  OVA-treated 
IL-4  -/-  mice were all either undetectable or markedly reduced compared with wild-type 
mice, confirming that IL-4 was required in this allergic model. These results indicate that the 
NKI.1 + 0t/J3  + T  cell population, as well as other [32m-dependent populations, such as most 
peripheral od[3 + CD8 + T  cells, are dispensable for the Th2 pulmonary response to protein al- 
lergens. 
C 
Ytokines produced by T  cells are critical regulators of 
the immune response to pathogens and antigens (1, 2). 
CD4 +  effector and  memory  T  cells  that  develop  during 
chronic  immune  responses  tend  to  express  cytokines  in 
mutually exclusive patterns of either the T  helper cell (Th)1 
(IL-2,  IFN-%  and  TNF-[3)  or  the  Th2  (IL-4,  IL-5,  and 
IL-13)  phenotypes  (1,  2).  Coordinate  production of Th2 
cytokines is  characteristic of responses  either to  infection 
with metazoan parasites  (2) or to repeated allergen exposure 
(3). The consequences ofTh2 cytokine expression include in- 
creased production of IgE by B  cells,  an  IL-4-dependent 
effect (4)  that,  at least in  humans,  may be  augmented by 
IL-13  (3),  as well as inflammation of tissues  with  eosino- 
phils, a feature that is IL-5 dependent (5-7). Recent studies 
also suggest that Ix/13  + CD8 + T  cells are a potential source 
ofTh2 cytokines, such as IL-4 and IL-5 (1, 8). 
Several lines of evidence suggest that IL-4 itself plays  a 
central role in  Th2  cell development in vivo.  First,  mice 
deficient in IL-4, as a result of disruptive gene targeting, fail 
to  develop  IL-5-producing  T  cells  or  eosinophilia  after 
challenges with helminths or allergens  (9, 10). Second, treat- 
ment of wild-type mice with neutralizing antibodies against 
IL-4  during  primary  immunization  with  protein  antigen 
reduces subsequent antigen-specific production of IL-4 by 
T  cells ex vivo and IL-4 mRNA expression by splenocytes 
in vivo (11,  12). Third, studies of the differentiation of an- 
tigenically naive T  cells in vitro demonstrate that IL-4 pro- 
motes Th2-1ike differentiation (13). 
Since IL-4 production by antigenically naive T  cells  in 
response to conventional protein antigens or polyclonal ac- 
tivators tends to be low (14),  other cellular sources of IL-4 
production have been proposed to promote Th2 differenti- 
ation. These include non-T-lineage cells, such as mast cells 
and basophils (15),  as well as cells of T-lineage, such as the 
murine NKI.1 + Ix/J3  + T  cell population (2,  16).  NKI.1 + 
c~/[3  + T  cells are either CD4 + or CD4-~ED8- by their cell 
surface  phenotype  (16)  and  have  been  shown  to  rapidly 
produce relatively high levels of IL-4 after activation with 
anti-CD3  monoclonal  antibody  treatment  in  vivo  (17). 
Murine NKI.1 + T  cells require [32-microglobulin (132m)- 
expressing  hematopoietic  cells  for  their  development  in 
vivo (18),  and the T  cell receptors of at least some of these 
cells recognize antigens bound to CD1, a nonclassic MHC 
molecule that associates with [32m on the cell surface (16). 
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lack  the  NKI.1 +  T-lineage  cell  population,  have  an  im- 
paired  ability to  produce  IgE  in  response  to  polyclonal 
activation in vivo induced by anti-CD3 mAb or goat anti- 
mouse  IgD  serum  (19).  However,  it  remains  unclear 
whether NKI.1 +  T  cells are essential for IgE and other as- 
pects  of Th2  immunity  induced by  conventional protein 
antigens  or if other T  cells are  important  in  this  context, 
such as o~/13  + CD8 + T  cells. 
Using a murine model of OVA-induced allergic pulmo- 
nary disease that  requires  IL-4 production,  we  show  here 
that [32m-dependent T  cell populations are dispensable for 
a  robust Th2  immune  response, including antigen-specific 
and total IgE expression, tissue eosinophilia, and increased 
expression of Th2  cytokines in  lung-associated peripheral 
lymphoid tissue. These results suggest that neither NKI.1 + 
or/]3 +  T  cells nor  conventional o~/13  +  CD8  T  cells play a 
critical role in directing Th2 cell differentiation ii: vivo and 
that  other  cell  types  may  provide  sufficient  IL-4  for  this 
process. 
Materials and Methods 
Animals.  Wild-type  C57BL/6J  mice  were  obtained  from 
Jackson  Laboratories  (Bar  Harbor,  ME).  ~2m  -/-  mice  ho- 
mozygous for targeted disruption of the 132m gene (20) and con- 
genic on the C57BL/6J background were generously provided by 
Dr. Christopher Wilson (University of Washington). These mice 
were confirmed to be homozygous for the mutant ~2m allele by 
staining with immunofluorescent mAbs and FACS  |  analysis (Bec- 
ton Dickinson & Co., Inc., Mountain View, CA), which demon- 
strated the  expected decrease  in  numbers  of CD4-CD8 +  thy- 
mocytes, peripheral CD8 +  T  cells,  and  splenic NKI.1 +  T  cells 
compared with  wild-type mice  (19,  20).  IL-4  -/-  mice  ho- 
mozygous for targeted disruption of the IL-4 gene  (4) were ob- 
tained from Dr. B.J.  Fowlkes (National Institutes of Health, Be- 
thesda, MD)  and were used after 10 generations of backcrossing 
onto  a  C57BL/6J  background. All mice were  housed in a  spe- 
cific-pathogen-free facility and were 8-12 weeks old. 
Experimental Protocol  for the Induction of Allergic Pulmonary Dis- 
ease.  OVA-treated mice  received single  intraperitoneal injec- 
tions  of 100  ~g  of alum-precipitated crystalline OVA  (Pierce, 
Rockford, IL) in 0.2 ml of normal saline  on day 1 and day 14, 
and single intranasal doses of 50 ~g of OVA in 50 ~1 of normal 
saline on day 14, day 25, day 26, and day 27 as described previ- 
ously  (21).  Sham-sensitized  mice  were  treated  identically  to 
OVA-treated mice except that intraperitoneal injections consisted 
of 0.2 m/of alum in normal saline,  and intranasal doses consisted 
of 50  ~1 of normal saline. Mice were euthanized on day 28, and 
plasma, bronchoalveolar lavage fluid, and bronchial lymph node 
tissue were collected. 
Total and OVA-specific IgE ELISA.  For determination of total 
IgE, ELISA plates (ICN,  Costa Mesa, CA) were  coated with 2 
~g/in/  of rat  anti-mouse  IgE  mAb R35-72  (rat  IgG1  isotype; 
Pharmingen, San Diego, CA) in PBS  (pH 7.4)  overnight at 4~ 
Wells were blocked by incubation with PBS and 3% BSA for 2 h. 
Plasma  samples or a  purified murine  monoclonal  IgE  standard 
(clone  IgE-2,  IgE6; Pharmingen)  were  diluted in  PBS  with  3% 
(wt/vol) BSA and applied for 1.5 h, followed by incubation for 1 h 
with peroxidase-conjugated rat anti-mouse IgE mAb LO-ME-3 
(rat  IgG1  isotype; Biosource  International,  Camarillo,  TX)  di- 
luted  1:500  in  PBS  with  50%  (vol/vol)  normal  goat  serum 
(GIBCO BRL, Gaithersburg, MD). Enzyme substrate was added, 
and well absorbance at 630 nm was determined as described (21). 
OVA-specific IgE levels were determined by ELISA using stan- 
dard  methods  (21).  A  pooled  plasma  from  OVA-immunized 
BALB/c mice, arbitrarily assigned an  OVA-specific IgE  titer of 
10 U/m/, was included in each assay as a standard. 
Bronchoalveolar Lavage.  Bronchoalveolar lavage (BAL) fluid was 
obtained as previously described (21). The final pooled BAL fluid 
volume was routinely between 0.9 and 1.1  ml. Cells in the BAL 
fluid were resuspended, and a small aliquot (50  txl) was  counted 
using a hemocytometer. The remaining fluid was  centrifuged at 
4~  for  10 min at 200 g, and the cell pellet was  resuspended in 
0.1  m/  of normal saline containing 10% BSA (Calbiochem, San 
Diego, CA), applied to microscope slides, and dried. Slides were 
stained with a solution of 0.05%  (wt/vol) aqueous eosin Y (Sigma 
Chemical  Co.,  St.  Louis,  MO)  and  5%  (vol/vol)  acetone  and 
counterstained  with  0.07%  (wt/vol)  methylene  blue  (Allied 
Chemical Technologies, Inc., Morristown, NJ) in distilled water. 
Reverse  Transcriptase-PCR  of  Bronchial  Lymph  Node  Tissue. 
Total RNA was isolated from bronchial lymph nodes, and 4  ~g 
of total RNA per sample was reverse transcribed (21).  PCR was 
performed for 35  cycles using the temperature and buffer condi- 
tions and the primer sequences for murine  hypoxanthine phos- 
phoribosyl transferase  (HPRT),  IL-4, IL-5, and IL-13, as previ- 
ously described (21, 22), with the input ofcDNA template either 
100  ng  (HPRT  and  IL-4),  200  ng  (IL-13),  or  500  ng  (IL-5). 
PCR amplification of HPRT and IL-4 transcripts was performed 
in the presence of 0.075 pg of a competitor plasmid, pQRS (22), 
provided by Dr.  Richard Locksley (University of California at 
San  Francisco).  The  competitor plasmid was  not included in the 
IL-13 and IL-5 amplifications, since,  in preliminary experiments, 
this led to a complete loss of detectable IL-5 mRNA-derived or 
IL-13 mR.NA-derived products. PCR products were analyzed by 
agarose gel electrophoresis and ethidium bromide staining. 
Results and Discussion 
To determine the importance of [32m-dependent T  cells 
for the development of Th2  responses in vivo, ~2m  -/-, 
and wild-type C57BL/6 mice were treated with OVA by a 
Table 1.  Plasma  Total and OVA-spec!fic IgE Levels in 
Wild-type,  ~2m  -/-,  and IL-4  -/-  Mice 
Mouse Strain  Total IgE  OVA-specific IgE 
and Treatment  (ng/ml)  (U/ml) 
Wild-type, OVA (n =  11) 
r  -/-,  OVA (n =  12) 
IL-4 -/-,  OVA (n =  11) 
Wild-type, sham (n =  8) 
[32m -/-,  sham (n =  5) 
1144  +  368*  7.2 +  0.9* 
1536  --_ 424*  6.5  ~  1.1" 
16  __-+ 0  0.8 +  0.3 
64  +  2  <0.1 
160  ~- 64  <0.1 
Mean  +  SEM are shown. The data are representative of two indepen- 
dent  experiments.  There  were  no  significant differences in  total  or 
OVA-specific IgE levels between  wild-type mice and ,82m -/-  mice 
after OVA treatment. 
*P <0.05 for wild-type or 132m -/-  mice after OVA treatment versus 
all other groups by ANOVA. 
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stained with eosin and methylene 
blue.  (A)  fl2m -/-  mice after 
treatment with  OVA. (B)  Wild- 
type  mice after treatment with 
OVA.  (C)  Wild-type  mice after 
sham sensitization. (D) IL-4 -~- 
mice after treatment with OVA. 
protocol that reliably induces OVA-specific IgE, eosinophil 
accumulation in the lung parenchyma and airway,  and in- 
creased expression ofTh2 cytokines in bronchial lymph nodes 
from mice of the C57BL/6 strain  (21). OVA-treated wild- 
type mice had >  10-fold higher mean plasma levels of total 
IgE than  sham-sensitized  wild-type  animals  (Table  1).  As 
expected, OVA-specific IgE was demonstrable in the plasma 
of OVA-treated  wild-type  mice  but  was  undetectable  in 
samples  from  sham-sensitized  wild-type  mice  (Table  1). 
The plasma levels of total and OVA-specific IgE in OVA- 
treated  [32m  -/-  mice  were  similar  to  those  of OVA- 
treated  wild-type  animals  (Table  1),  indicating  that  IgE 
production was unperturbed. 
Our  results  differ  from those  of Yoshimoto  et  al.  (19), 
who found markedly lower total  IgE levels  in fl2m  -~- 
mice compared with wild-type C57BL/6 mice 9 d after in- 
jection with  goat anti-mouse  IgD serum.  In these  experi- 
ments,  the  IgE  response  of fl2m  -/-  mice  to  anti-lgD 
injection  as  well  as  the  NKI.1 +  T  cell  population  was 
reconstituted  to  wild-type  levels  by  adoptive  transfer  of 
NKI.1 + thymocytes and T  cell-depleted  splenocytes from 
wild-type animals (19). There are at least three possible ex- 
planations why the induction of IgE by anti-IgD treatment 
may require  NKI.1 §  T  cells,  whereas  immunization  with 
protein  antigen  does  not.  First,  NKI.1 +  T  cells  might be 
needed for IgE production in situations in which B cells are 
the principal APC for T  cells,  as appears to be the case for 
anti-IgD  treatment  (23),  but might be  dispensable  for IgE 
produced  after  immunization  with  conventional  protein 
antigens, a situation in which other APC, particularly den- 
dritic  cells,  are  likely  to  be  important  (24).  Second,  it  is 
possible that IgE induced after primary immunization with 
protein  antigen  may  be  dependent,  at  least  in  part,  on 
NK1.1 + T  cells,  but that this requirement is abrogated with 
secondary and additional immunizations.  However, we do 
not  favor  this  possibility  since  fl2m  -/-  and  wild-type 
mice had similar levels of OVA-specific IgE 9 d  after a sin- 
gle intraperitoneal injection of alum-precipitated OVA (the 
OVA-specific IgE titer  [mean +  SEMI in fl2m  -/-  mice 
In =  5] and wild-type mice [n =  4] was 2.33  +  0.97 U/rnl 
and 1.86  +  0.44 U/ml,  respectively;  P  =  0.7 by the two- 
tailed,  unpaired  Student's  t test).  A  third possibility is  that 
during development in fl2m -/-  mice, another subpopu- 
lation of T  cells is able to produce IL-4, and to compensate 
for the loss ofNKl.1 +  T  cells  or other  [32m-dependent 
T  cells. 
We  analyzed  BAL  fluid  obtained  on  day  28  of OVA 
treatment to determine if the pulmonary leukocyte inflam- 
matory response was altered in fl2m  -/-  mice compared 
with  wild-type  mice.  In  both  fl2m  -/-  and  wild-type 
mice, OVA treatment resulted in a significantly greater to- 
tal number of cells  in the BAL fluid compared with that of 
sham  sensitization  (Table  2),  with  eosinophils  comprising 
the majority of cells  (Table 2 and Fig. 1, A  and B). Eosino- 
phils were not observed in sham-sensitized controls of either 
Table 2.  Bronchoalveolar  Lavage Fluid Leukocytes in Wild-type, 
fl2m  -/-,  and IL-4 -/-  Mice 
Mouse Strain  Cell Number  Percentage of 
and Treatment  (￿  104/ml)  Eosinophils 
Wild-type, OVA (n =  11) 
fl2m  -/-,  OVA (n =  12) 
IL-4 -/-,  OVA (n =  11) 
Wild-type, sham (n =  8) 
fl2m  -/-,  sham (n =  5) 
98.4 +-- 31.1"  66.8  -+ 1.8" 
111.4  -+ 17.9"  65.5  +-- 2.2* 
18.1  +  2.3  2.0 +- 0.9 
7.0 -+ 0.9  <0.1 
7.6 +  1.7  <0.1 
Mean -+ SEM are shown. The data are representative of two indepen- 
dent experiments. There were no significant differences between wild- 
type mice and fl2m -/-  mice after OVA treatment. 
*  P <0.05 for wild-type or fl2m -/-  mice after OVA treatment versus 
all other groups by ANOVA. 
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of HPRT and cytokine mRNA 
levels  in  the  bronchial  lymph 
node tissue of  individual nfice. (A) 
HPRT,  IL-4,  lL-5, and  1L-13 
1LNA  expression  in  wild-type 
mice  (lanes 1-7)  or  ~fl2m -~- 
mice (lanes 8-13) after sham sen- 
sitization (lanes 1-3, 8, 9) or after 
OVA  treatment  (lanes 4-7,  10- 
13). (B) HP1LT, IL-5, and IL-13 
RNA  expression  in  wild-type 
mice  (lanes 1-6) or  IL-4  -~- 
mice (lanes 7-10) after sham sen- 
sitization  (lanes 1-3)  or  after 
OVA  treatment  (lanes 4-10). 
MW  Stds indicates the  123  bp 
molecular weight standard ladder 
(GIBCO BRL). For the HPRT 
and IL-4 panels, the position of 
products amplified  from the pQtkS 
competitor  plasmid (comp)  or 
from endogenous wild-type tran- 
scripts (W7) are indicated. 
the fl2m  -/-  or wild-type groups  (Table  1 and Fig.  1  C). 
Furthermore,  a  marked  eosinophilic  infiltrate  in  the  pul- 
monary parenchyma was also  observed for 132m -/-  and 
wild-type mice after OVA treatment,  but not in sham-sen- 
sitized animals (data not shown). 
Previous work using mice has shown that eosinophil ac- 
cumulation  in  the  lung  and  airway  in  response  to  OVA 
treatment  requires  the  Th2  cytokines,  IL-4  (10)  and  IL-5 
(5),  and  is  associated  with  locally  increased  expression  of 
these  cytokines  (7).  To  determine  if the  eosinophilic  pul- 
monary  inflammation  in  132m -/-  and  wild-type  mice 
was  accompanied  by locally  increased  production  of Th2 
cytokines  by  lymphocytes,  the  amount  of cytokine  tran- 
scripts in the draining bronchial lymph nodes from individ- 
ual  animals  was  analyzed  by  reverse  transcriptase  (RT)- 
PC1L  (Fig.  2).  The  bronchial  lymph  nodes  of wild-type 
mice or ~2m  -/-  mice treated with OVA (Fig. 2 A, lanes 
4-7 and lanes  10-i3,  respectively)  had substantially higher 
levels  of transcripts  for  IL-4,  IL-5,  and  IL-13  compared 
with  those from sham-sensitized  controls  (lanes  1-3,  8,  9). 
Cytokine  mRNA  levels  in  wild-type  or  B2m  -/-  mice 
were  low  to  undetectable  after  sham  sensitization  (Fig.  2 
A).  These  higher  cytokine  levels  in  OVA-treated  samples 
were not attributable to an increased amount of total RNA 
that was amplifiable by PCR,  since  the ratio  of the R.NA- 
derived  and  competitor-derived  products  for  HPRT,  an 
abundant  housekeeping  gene,  was  similar  in  all  samples. 
The amount of competitor-derived  IL-4 products was also 
similar in  all lanes,  indicating  that  the  overall efficiency of 
PCR  amplifications  did not vary significantly from sample 
to  sample.  The  increase  in  Th2  cytokine  abundance  in 
bronchial  lymph  node  tissue  suggested  that  activation  of 
T  cells in vivo by allergen occurred normally in ~2m  -~- 
mice.  Consistent  with  this  idea,  we  also  found  that  bron- 
chial  lymph  node  cells  from  OVA-treated  ~2m  -/-  or 
wild-type mice had similar levels of OVA-specific cell pro- 
liferation  in  vitro  (data  not  shown).  Together,  these  data 
indicate  that  T  cell  priming  by  antigen  and  expression  of 
Th2-type cytokines occurred normally in ~2m  -/-  mice. 
Our  results  are  consistent  with  those  of Guery et  al.  (25), 
who found  that continuous  administration  of low doses of 
soluble  protein  antigens  to  either  wild-type  or ~2m  -/- 
BALB/c  mice resulted  in  Th2-1ike  cells  that preferentially 
produced  IL-4,  rather  than  IFN-',/,  after  stimulation  with 
antigen  ex vivo.  Our  results  extend  these  observations  by 
demonstrating  that  [32m-dependent  T  cell populations  are 
dispensable  in  C57BL/6  strain  mice  for  multiple  in  vivo 
events characteristic  of the allergic response. 
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flammation, and Th2 cytokine production induced in wild- 
type and 182m -/-  mfice by our OVA-treatment  protocol 
were  IL-4  dependent,  these  responses  were  analyzed  in 
IL-4 -/-  mice. As expected, based on earlier studies (4, 6), 
OVA-treated  IL-4  -/-  mice  had  substantially  decreased 
plasma  levels  of total  and  OVA-specific  IgE  compared 
with  wild-type  mice  (Table  1).  The  low  but  detectable 
amount  of total and OVA-specific  IgE in IL-4 -/-  mice 
suggests  that a  portion  of IgE production  in vivo may be 
IL-4 independent and is consistent with a report of reduced 
but  detectable  levels  of total  IgE  in  IL-4  -/-  mice  in- 
fected with Plasmodium (26). Both BAL fluid cellularity and 
eosinophilia  (Table 2 and Fig.  1 D) were also markedly de- 
creased  in  IL-4 -/-  mice compared with  wild-type  ani- 
mals.  Consistent  with  these  findings,  which  suggested  a 
decreased Th2 immune response in vivo, the levels of IL-5 
and IL-13 mRNA  in the bronchial lymph nodes of OVA- 
treated  IL-4  -/-  mice  were  dramatically  reduced  com- 
pared with wild-type mice (Fig. 2 B). These results also in- 
dicate  that  IL-13  expression  during  allergic  reactions  in 
vivo is largely IL-4 dependent,  at least in mice. 
Our  results  also  suggest  that  most  conventional  ot/t3 + 
CD8 +  T  cells  are  dispensable  for the  Th2  pulmonary  re- 
sponses to OVA.  This contrasts with a report (27) in which 
treatment  of  thymectomized  BALB/c  mice  with  anti- 
CD8-a  mAb  prevented  OVA-induced  eosinophil  accu- 
mulation  and IL-5 mRNA  expression by bronchial lymph 
nodes.  Whether  these  different  results  reflect  the  strains 
used--C57BL/6  versus  BALB/c--or  the  methods  em- 
ployed to eliminate  CD8  T  cells--genetic  versus thymec- 
tomy  and  antibody  treatment--remains  unresolved.  It  is 
possible  that  anti-CD8-a  mAb  treatment  may  eliminate 
mucosal CD8 + T  cells that are required for the allergic pul- 
monary response, but which are not dependent on 132m for 
their development, such as CD8 + y/B + T  cells (28). Inter- 
estingly,  a  population  of  NKI.1 +  ~//8 +  thymocytes  is 
present in fl2m -/-  mice, and like NKI.1 + a/13 + T  cells, 
these  ceils rapidly produce  IL-4 after polyclonal activation 
(29).  Therefore,  peripheral  T  cells  derived  from  this 
NKI.1 +  ~//8 +  thymocyte  population  could  provide  IL-4 
for Th2  cell  differentiation  in  ~2m  -/-  as  well  as  wild- 
type mice. Whether  this  cell population  expresses CD8-ot 
in the periphery remains to be determined. 
In  summary,  our  results  indicate  that  the  Th2  allergic 
pulmonary response induced by OVA in this model is IL-4 
dependent but independent  of [32m expression. This argues 
that  132m-dependent  oL/13  + T  cells,  such as NKI.1 + 0t/~ + 
T  cells, and most class I MHC-restricted a/13 + CD8 T  cells 
are dispensable  for a  robust Th2  response to protein  aller- 
gens in vivo. Further studies are required  to determine  the 
importance  of other  cellular  sources  of IL-4  proposed  to 
influence  Th2  differentiation,  such  as mast cells and baso- 
phils, conventional ot/13 + T  cells, or ~//8 + T  cells (2,  15). 
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